Quest Diagnostics 1998 Annual Report Download - page 10

Download and view the complete annual report

Please find page 10 of the 1998 Quest Diagnostics annual report below. You can navigate through the pages in the report by either clicking on the pages listed below, or by using the keyword search tool below to find specific information within the annual report.

Page out of 13

  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • 7
  • 8
  • 9
  • 10
  • 11
  • 12
  • 13

13
insights
12
through unsurpassed diagnostic
Knowledge plus experience yields insights. We offer insights
that improve patient care in a variety of ways. At the world-
renowned Nichols Institute, our specialty laboratory and
research and development center, insights emerge from our
review of a steady stream of cases that are rarely seen anywhere
else. Nichols Institute is the “laboratory’s laboratory,” drawing
unusual cases not only from Quest Diagnostics’ own network,
but also from hospital labs and other independent labs. At
Quest Informatics, insights come from our ability to detect
patterns in vast databases containing hundreds of millions
of ordinary test results. Managed care providers and
pharmaceutical companies use this valuable information
resource to identify patients at risk for certain diseases
for early treatment. Our insights enable us to help bring
patients the benefits of new technology. Since the 1970s,
Nichols Institute has been a leader in tests for breast tumor
markers—tests not only to diagnose disease, but to help
physicians manage therapy by predicting a patient’s response
to a given treatment. In 1998, Quest Diagnostics became the
first national laboratory to offer the HercepTest assay,
approved by the FDA to identify women who are likely to
benefit from Herceptin, a new monoclonal antibody therapy
for metastatic breast cancer developed by Genentech, Inc.
Clockwise, from top: Michael Samoszuk, M.D., Medical & Scientific Director, Oncology, Nichols Institute; Michael Lewinski, Ph.D., Scientific Director,
Infectious Diseases, Nichols Institute; Delbert Fisher, M.D., Chief Science Officer, Nichols Institute; Avelino Diao, Molecular Microbiology Lab Supervisor,
Nichols Institute Reference Laboratory; Raj Pandian, Ph.D., Science Leader, Nichols Institute Reference Laboratory; Scott Todd, Human Resources Manager,
Nichols Institute; Salli Schwartz, Supervisor, Referral Testing, Horsham; Geoffrey Gottlieb, M.D., Dermatopathologist, Teterboro; and Candice Miller, Quest
Informatics Business Leader.